Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care
Launched by NEW YORK UNIVERSITY · Sep 16, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on helping people living with HIV who smoke to quit smoking. The goal is to find effective and affordable ways to support these individuals in their journey to stop smoking while ensuring that healthcare staff can easily manage the program. By improving smoking cessation efforts in HIV care, the study aims to enhance the overall health of smokers living with HIV.
To be eligible for this study, participants must be at least 18 years old, currently smoke a minimum of five cigarettes a day, and be diagnosed with HIV. Additionally, they need to be engaged in HIV clinical care and live in the larger New York City area for the next 6-8 months. Those who have certain medical conditions, are pregnant or nursing, or are currently using other smoking cessation aids will not be able to participate. If you join this trial, you can expect to receive support and resources tailored to help you quit smoking, all while contributing to important research that could benefit others in similar situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Status as HIV+
- • Age 18 or older
- • Currently smokes ≥ 5 CPD, on average, in past month
- • Positive for salivary cotinine
- • Able to understand the nature of the study and the consenting process
- • Is engaged in HIV clinical care
- • Living in larger NYC metropolitan area currently and for the next 6-8 months
- Exclusion Criteria:
- • Suffers from any medical condition or contraindication precluding use of nicotine replacement therapy
- • Current use of any tobacco cessation medications (varenicline, NRT patch, nicotine gum, lozenge, spray or inhaler, or bupropion)
- • Currently participating in a smoking cessation program
- • Pregnant or nursing and plans to be in next 6 months
- • Has schizophrenia/schizo-affective disorder
- • Does not have a functioning mobile phone that can receive text messages
About New York University
New York University (NYU) is a prestigious research institution renowned for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust infrastructure and a diverse team of leading experts, NYU conducts cutting-edge research across various therapeutic areas, focusing on translating scientific discoveries into effective treatments. The university fosters collaboration among multidisciplinary teams and engages with a broad patient population, ensuring that its trials adhere to the highest ethical standards and regulatory requirements. NYU's dedication to excellence in research and education positions it as a key contributor to the advancement of healthcare and clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported